- Home
- MASS vs ANL Comparison
MASS vs ANL Comparison
Compare MASS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- ANL
- Stock Information
- Founded
- MASS 2012
- ANL 2004
- Country
- MASS United States
- ANL Cayman Islands
- Employees
- MASS N/A
- ANL N/A
- Industry
- MASS Medical/Dental Instruments
- ANL
- Sector
- MASS Health Care
- ANL
- Exchange
- MASS Nasdaq
- ANL Nasdaq
- Market Cap
- MASS 117.5M
- ANL 115.1M
- IPO Year
- MASS 2020
- ANL 2023
- Fundamental
- Price
- MASS $2.74
- ANL $2.77
- Analyst Decision
- MASS Buy
- ANL Strong Buy
- Analyst Count
- MASS 3
- ANL 2
- Target Price
- MASS $8.00
- ANL $9.00
- AVG Volume (30 Days)
- MASS 346.0K
- ANL 29.8K
- Earning Date
- MASS 11-12-2024
- ANL 08-08-2024
- Dividend Yield
- MASS N/A
- ANL N/A
- EPS Growth
- MASS N/A
- ANL N/A
- EPS
- MASS N/A
- ANL N/A
- Revenue
- MASS $55,162,000.00
- ANL $5,000,000.00
- Revenue This Year
- MASS $29.30
- ANL N/A
- Revenue Next Year
- MASS $26.50
- ANL N/A
- P/E Ratio
- MASS N/A
- ANL N/A
- Revenue Growth
- MASS 16.08
- ANL N/A
- 52 Week Low
- MASS $2.19
- ANL $1.85
- 52 Week High
- MASS $12.51
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- MASS 35.98
- ANL 53.97
- Support Level
- MASS $2.32
- ANL $2.50
- Resistance Level
- MASS $2.61
- ANL $3.50
- Average True Range (ATR)
- MASS 0.25
- ANL 0.47
- MACD
- MASS -0.08
- ANL -0.00
- Stochastic Oscillator
- MASS 18.28
- ANL 40.48
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.